Lutathera cancer therapy
Ended Awarded
- Contract number
- 36C26126F0008
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $679,949
Award facts
- Contract value 20% obligated
-
- $679,948.64 Current, with exercised options
- $3,399,743.20 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
About this award
Novartis Pharmaceuticals Corporation has been awarded a delivery order valued at $3.4 million for the supply of LUTATHERA cancer therapy to the Veterans Integrated Service Network 21 (VISN 21), a component of the Department of Veterans Affairs. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 30, 2030, and was awarded on October 1, 2025. The award is placed against Novartis' existing Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), which enables the VA to procure specialized radiopharmaceutical treatments for veteran patients. No small business set-aside designation was applied to this award, reflecting Novartis' status as a large pharmaceutical manufacturer competing directly in the federal marketplace.
This delivery order is issued under a larger Indefinite Delivery Contract (IDC) with a ceiling value of $26.1 million that was previously awarded to Novartis by the Defense Health Agency for cancer therapy drugs including LUTATHERA and PLUVICTO, running through September 30, 2029. The LUTATHERA therapy represents part of Novartis' broader portfolio of advanced oncological treatments supplied to the federal healthcare system, supporting specialized medical treatment programs across multiple VA networks and the Defense Health Agency. The contract will be performed in East Hanover, New Jersey, where Novartis maintains its pharmaceutical manufacturing and distribution operations.
Quick answers
Who was awarded contract 36C26126F0008?
36C26126F0008 was awarded to Novartis Pharmaceuticals Corporation by Veterans Integrated Service Network 21 (Veterans Health Administration) on October 1, 2025.
How much is contract 36C26126F0008 worth?
The government has obligated $679,949 on 36C26126F0008. Its potential value, with all options, is $3,399,743.
Is contract 36C26126F0008 an order under another contract?
Yes. 36C26126F0008 is a delivery order under 36F79720D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26126F0008 competed?
The extent of competition for 36C26126F0008 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award